New Model for Predicting Drug Distribution in Tumor and Normal Tissues

Strategic Insights -

Recent research from University of London, Imperial College, has developed a new system analysis modeling approach to characterize drug distribution in tissues based on human positron emission tomography (PET) data. This innovative method, applied to temozolomide, an important alkylating agent used in the treatment of brain tumors, has shown promising results in predicting normal brain and brain tumor temozolomide concentration profiles. The study, published in Cancer Research, has shed new light on the pharmacokinetics of temozolomide in glioma patients, providing valuable insights for the selection of rational dosing schedules.

Key Takeaways:

  • The proposed system analysis modeling approach uses PET data to characterize drug distribution in tissues.
  • The method was applied to temozolomide, an alkylating agent used in the treatment of brain tumors.
  • Predicted peak concentrations of temozolomide ranged from 2.9 to 6.7 μg/mL in human glioma tumors and from 1.8 to 3.7 μg/mL in normal brain.
  • The total drug exposure, as indicated by the tissue/plasma area under the curve ratio, was about 1.3 in tumor compared with 0.9 in normal brain.
  • The higher temozolomide exposures in brain tumor relative to normal brain were attributed to breakdown of the blood-brain barrier and possibly secondary to increased intratumoral angiogenesis.
  • The method is considered a robust tool to analyze and predict tissue drug concentrations.
  • The study has important implications for the selection of rational dosing schedules for temozolomide treatment in glioma patients.

Statistics:

  • Predicted peak concentrations of temozolomide in human glioma tumors ranged from 2.9 to 6.7 μg/mL.
  • Predicted peak concentrations of temozolomide in normal brain ranged from 1.8 to 3.7 μg/mL.
  • The total drug exposure in tumor was about 1.3 times higher than in normal brain.
  • The blood-brain barrier breakdown was attributed to a significant increase in temozolomide exposures.

Sources:

  • L. Rosso et al., "A New Model for Prediction of Drug Distribution in Tumor and Normal Tissues: Pharmacokinetics of Temozolomide in Glioma Patients." Cancer Research 2009;69(1):120-127.
  • American Association for Cancer Research. Cancer Research. 615 Chestnut St., 17th Floor, Philadelphia, PA 19106-4404, USA.